{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Tsiknia AA"],"funding":["NIA NIH HHS","Foundation for the National Institutes of Health","NINDS NIH HHS"],"pagination":["4314-4322"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9718670"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["27(10)"],"pubmed_abstract":["Studies have shown that women on the Alzheimer's disease (AD) continuum have more pathological tau in the brain and cerebrospinal fluid (CSF), than men. Some studies have found that higher levels of tau biomarkers are more strongly associated with clinical AD, cognitive decline and neurodegeneration in women than in men. Despite major developments in the use of plasma tau phosphorylated at threonine 181 (p-tau181) as an AD biomarker, it is unknown whether these sex differences apply to plasma p-tau181. In 1060 Alzheimer's Disease Neuroimaging Initiative (ADNI) participants (47% women, 73.8 ± 7.6 years old), we examined sex differences in plasma p-tau181 levels and their association with other biomarkers, cognitive decline and incident AD. Linear regressions tested for an effect of sex on p"],"journal":["Molecular psychiatry"],"pubmed_title":["Sex differences in plasma p-tau181 associations with Alzheimer's disease biomarkers, cognitive decline, and clinical progression."],"pmcid":["PMC9718670"],"funding_grant_id":["R25 NS117367","R01 AG074221","1R01AG066088-01, 1P30AG062429-01","R01 AG066088","U01 AG024904","P30 AG062429"],"pubmed_authors":["Sundermann EE","Galasko D","Banks SJ","Tsiknia AA","Edland SD","Brewer JB","Reas ET","Alzheimer’s Disease Neuroimaging Initiative"],"additional_accession":[]},"is_claimable":false,"name":"Sex differences in plasma p-tau181 associations with Alzheimer's disease biomarkers, cognitive decline, and clinical progression.","description":"Studies have shown that women on the Alzheimer's disease (AD) continuum have more pathological tau in the brain and cerebrospinal fluid (CSF), than men. Some studies have found that higher levels of tau biomarkers are more strongly associated with clinical AD, cognitive decline and neurodegeneration in women than in men. Despite major developments in the use of plasma tau phosphorylated at threonine 181 (p-tau181) as an AD biomarker, it is unknown whether these sex differences apply to plasma p-tau181. In 1060 Alzheimer's Disease Neuroimaging Initiative (ADNI) participants (47% women, 73.8 ± 7.6 years old), we examined sex differences in plasma p-tau181 levels and their association with other biomarkers, cognitive decline and incident AD. Linear regressions tested for an effect of sex on p","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Oct","modification":"2026-06-04T12:27:39.743Z","creation":"2025-02-19T04:20:26.792Z"},"accession":"S-EPMC9718670","cross_references":{"pubmed":["35768637"],"doi":["10.1038/s41380-022-01675-8"]}}